JXJT yields 247.68% · ABBV yields 3.06%● Live data
📍 JXJT pulled ahead of the other in Year 1
Combined, JXJT + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JXJT + ABBV for your $10,000?
JX Luxventure Limited, a casual menswear company, designs, develops, markets, and sells fashion menswear products in the People's Republic of China. The company operates through five segments: Wholesale, Retail, Contract Manufacturing, Tourism Service, and Cross-Border E-Commerce. It offers apparel products, including cotton and down jackets, sweaters, suits, shirts, T-shirts, jeans, and trousers; accessories, such as shoes, bags, belts, socks, and caps; and footwear for urban males between the ages of 20 and 40. As of December 31, 2021, the company owned and operated 1 corporate store and 29 franchised stores. It also provides packaged group tour services online through the Luxventure platform; and engages in the offline wholesale of health care, personal care, cosmetics, maternal and child, pet-related, and universal cuisine and household products, as well as online. In addition, the company offers tourism and selling carrier services. The company was formerly known as KBS Fashion Group Limited and changed its name to JX Luxventure Limited in October 2021. JX Luxventure Limited is headquartered in Haikou, the People's Republic of China.
Full JXJT Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.